Figure 3

Deletion of miR-301a reduces colitis-associated colon cancer development. (a) Study timeline of CAC and representative overview of colon from treated WT (n=10) and miR-301a^−/− (n=10) mice. (b) Hematoxylin and eosin (H&E) histological sections of colon tumors from WT (n=10) and miR-301a^−/− (n=10) mice. Scale bars, 500 μm (left) and 100 μm (right). (c–e) Tumor number (c), tumor size (d), and tumor size distribution (e) in WT (n=10) and miR-301a^−/− (n=10) mice. Values are means±s.d. **P⩽0.01 indicates the significance of the differences between the indicated groups. (f) Cell proliferation in colon tumors from WT (n=10) and miR-301a^−/− (n=10) mice as determined by Ki67 staining. Scale bars, 50 μm. (g) Ki67-positive cell counts in tumor sections of WT (n=10) and miR-301a^−/− (n=10) mice. Values are means±s.d. **P⩽0.01 indicates the significance of the differences between the indicated groups. (h, i) Stat3 and NF-κB activation in colon tumors from WT (n=10) and miR-301a^−/− (n=10) mice was determined by immunohistochemistry by using antibodies against phospho-Stat3 (h) and phospho-p65 (i). Scale bars, 500 μm (left) and 100 μm (right).